<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094128</url>
  </required_header>
  <id_info>
    <org_study_id>P21-007</org_study_id>
    <nct_id>NCT05094128</nct_id>
  </id_info>
  <brief_title>A Study to Assess Disease Activity in Adult Participants With Ankylosing Spondylitis Who Receive Upadacitinib in a Real-world Setting</brief_title>
  <acronym>UpSPINE</acronym>
  <official_title>Effectiveness of Upadacitinib in Patients With Ankylosing Spondylitis Suffering From Typical Disease Activity and Pain in a Real-World Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Axial spondyloarthritis (axSpA), which encompasses radiographic axSpA (r-axSpA, also known as&#xD;
      ankylosing spondylitis [AS]) is an immune-mediated inflammatory disease primarily affecting&#xD;
      the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain&#xD;
      that might be difficult to distinguish from other causes of chronic back pain. Many&#xD;
      participants report persistent pain, including back pain, which impacts disease activity and&#xD;
      quality of life including creating burdens such as sleep disturbance, social isolation, loss&#xD;
      of productivity, as well as anxiety and depression. Despite this, there is a lack of detailed&#xD;
      data and knowledge on pain in radiographic-axial spondyloarthritis (r-axSpA), including pain&#xD;
      types, how it is localized, and how these different facets of pain are impacted by treatment.&#xD;
      This study will assess the real-world effectiveness of upadacitinib on early and sustained&#xD;
      pain control, and the association between pain and clinical/patient-reported outcomes in&#xD;
      radiographic axSpA participants.&#xD;
&#xD;
      Upadacitinib is being developed for the treatment of r-axSpA. Approximately 352 adult&#xD;
      participants with active r-axSpA will be enrolled in Germany.&#xD;
&#xD;
      Participants will receive oral upadacitinib tablets as prescribed by the physician prior to&#xD;
      enrolling in this study in accordance with the terms of the local marketing authorization and&#xD;
      professional and reimbursement guidelines with regards to dose, population and indication.&#xD;
      The overall duration of the study is approximately 52 weeks.&#xD;
&#xD;
      There may be a higher burden for participants in this study compared to usual standard of&#xD;
      care due to study procedures. Participants will attend regular visits per routine clinical&#xD;
      practice. The effect of the treatment will be checked by medical assessments, checking for&#xD;
      side effects, and questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score Low Disease Activity (ASDAS LDA [&lt; 2.1])</measure>
    <time_frame>Week 24</time_frame>
    <description>The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Low disease is defined as an ASDAS &lt; 2.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving ASDAS LDA (&lt; 2.1) (i.e., Maintenance of Response)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Low disease is defined as an ASDAS &lt; 2.1. Maintenance of response is defined as those achieving LDA at Week 24 and Week 52.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) Score of 40</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASAS-HI has been developed to measure functioning and health in patients with SpA with the aim of defining and comparing the impact of the disease and health based on the biopsychosocial model of disease proposed by the International Classification of Functioning, Disability and Health (ICF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score &lt; 4</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The BASDAI is a commonly used measure to define disease activity levels in r-axSpA patients. The overall BASDAI score ranges from 0 to 10, with higher scores indicating greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ASDAS Inactive Disease (ID [&lt; 1.3])</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Inactive disease is defined as an ASDAS &lt; 1.3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ASDAS LDA (&lt; 2.1)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASDAS is a composite index with proven validity and reliability to assess disease activity in r-axSpA participants, with LDA defined as a score &lt; 2.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BASDAI</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The BASDAI is a commonly used measure to define disease activity levels in r-axSpA patients. The overall BASDAI score ranges from 0 to 10, with higher scores indicating greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BASDAI at Week 1-4</measure>
    <time_frame>Week 4</time_frame>
    <description>The BASDAI is a commonly used measure to define disease activity levels in r-axSpA patients. The overall BASDAI score ranges from 0 to 10, with higher scores indicating greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) for Participants with Baseline Enthesitis</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The LEI is a clinical index used to assess enthesitis. It consists of 3 bilateral sites: Achilles tendon insertions, medial femoral condyles, and lateral epicondyles of the humerus. Tenderness at each site is quantified on a dichotomous basis: 0 means nontender and 1 means tender.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Resolution of Dactylitis for Participants with Baseline Dactylitis</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Presence of dactylitis (Yes/No) will be assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in ASAS-HI</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASAS-HI has been developed to measure functioning and health in patients with SpA with the aim of defining and comparing the impact of the disease and health based on the biopsychosocial model of disease proposed by the ICF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ASAS-HI &lt;= 4</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASAS-HI has been developed to measure functioning and health in patients with SpA with the aim of defining and comparing the impact of the disease and health based on the biopsychosocial model of disease proposed by the ICF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Nocturnal Back Pain in Past 24 Hours</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Pain will be measured using a 0 - 10 numerical rating scale (NRS) for nocturnal back pain (0 = no pain and 10 = most severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Total Back Pain in Past 24 Hours</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Pain will be measured using a 0 - 10 numerical rating scale (NRS) for nocturnal back pain (0 = no pain and 10 = most severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The BASFI is a validated PRO instrument for use in the r-axSpA patient population. It consists of 10 items measured on a 0 to 10 NRS, which assesses the ability to perform activities known to be problematic to r-axSpA patients such as dressing, bending, reaching, turning, and climbing steps. The total scores range from 0 to 10 with higher scores indicating worse physical functioning in r-axSpA patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Patient Health Questionnaire-4 (PHQ-4)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The 4-item PHQ-4 is an ultra-brief self-report questionnaire that consists of a 2-item depression scale (PHQ-2) and a 2-item anxiety scale (GAD-2). It is rated on a 4-point Likert-type scale. Its purpose is to allow for very brief and accurate measurement of depression and anxiety.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Radiographic Axial Spondylarthritis (r-axSpA)</condition>
  <arm_group>
    <arm_group_label>Participants Receiving Upadacitinib</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Participants Receiving Upadacitinib</arm_group_label>
    <other_name>RINVOQ</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with radiographic axial spondylarthritis (r-axSpA) who have been&#xD;
        prescribed upadacitinib in the course of routine practice according to relevant approved&#xD;
        licenses.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of r-axSpA upon physician's judgement.&#xD;
&#xD;
          -  Physician decision on participant treatment with upadacitinib must have been reached&#xD;
             prior to and independently of recruitment in the study.&#xD;
&#xD;
          -  Upadacitinib prescribed in accordance with the local label.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to&#xD;
             upadacitinib, tofacitinib, baricitinib, and filgotinib).&#xD;
&#xD;
          -  Participants with primary fibromyalgia (upon physician´s judgement)&#xD;
&#xD;
          -  Participation in a clinical trial of an investigational drug, concurrently or within&#xD;
             the last 30 days or five half-lives of the drug (whichever is longer) prior to the&#xD;
             first dose of study drug or is currently enrolled in another clinical study.&#xD;
&#xD;
          -  Participants who cannot be treated with upadacitinib according to the applicable local&#xD;
             label.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Praxis Dres. Kellerer/Kellerer/Krüger /ID# 240478</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81541</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistisches Praxiszentrum /ID# 240491</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet /ID# 240137</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet /ID# 240460</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kupka &amp; Kupka, Altenburg, DE /ID# 240479</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marycz, Amberg, DE /ID# 240483</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis am Webereck /ID# 240454</name>
      <address>
        <city>Augsburg</city>
        <zip>86157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis S. Bresgulewski /ID# 240662</name>
      <address>
        <city>Bad Bertrich</city>
        <zip>56864</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Bad Neuenahr /ID# 240441</name>
      <address>
        <city>Bad Neuenahr</city>
        <zip>53474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Weserbergland /ID# 240486</name>
      <address>
        <city>Bad Pyrmont</city>
        <zip>31812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACURA Rheumazentrum Baden-Bade /ID# 240487</name>
      <address>
        <city>Baden-baden</city>
        <zip>76530</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische-rheumatologische Praxisgemeinschaft /ID# 240496</name>
      <address>
        <city>Bayreuth</city>
        <zip>95444</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Rheumatologie /ID# 240614</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fuer Rheumatologie und Innere Medizin /ID# 240457</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Silke Zinke /ID# 240526</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisterhues, Braunschweig, DE /ID# 239438</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Rheumat /ID# 240450</name>
      <address>
        <city>Burghausen</city>
        <zip>84489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Versorgungszentrum AGILOMED /ID# 240481</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. Schuh /ID# 240498</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. Karger/Baerlecken /ID# 240442</name>
      <address>
        <city>Cologne</city>
        <zip>50996</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Demmin /ID# 240451</name>
      <address>
        <city>Demmin</city>
        <zip>17109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologisches MVZ Dresden /ID# 240516</name>
      <address>
        <city>Dresden</city>
        <zip>01109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Düren /ID# 240447</name>
      <address>
        <city>Düren</city>
        <zip>52355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dilltal /ID# 240520</name>
      <address>
        <city>Ehringshausen</city>
        <zip>35630</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Mueller, Freiberg, DE /ID# 240489</name>
      <address>
        <city>Freiberg</city>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Sensse/Sensse /ID# 240517</name>
      <address>
        <city>Gifhorn</city>
        <zip>38518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Goettingen /ID# 240138</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Liebhaber /ID# 240480</name>
      <address>
        <city>Halle</city>
        <zip>06128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilig, Heidelberg, DE /ID# 240492</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Bernd Mueller /ID# 240488</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis K. Pagel /ID# 240490</name>
      <address>
        <city>Hoppegarten</city>
        <zip>15366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer, Kaiserslautern, DE /ID# 240444</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alb-Donau Klinikum, Langenau /ID# 240446</name>
      <address>
        <city>Langenau</city>
        <zip>89129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamann &amp; Teich &amp; Boche,Leipzig /ID# 240445</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis internistische Rheumatologie /ID# 240515</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurich &amp; Sieburg, Magdeburg /ID# 240518</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Annekatrin Rossbach /ID# 240495</name>
      <address>
        <city>Mansfeld / Großörner</city>
        <zip>06343</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmuth, Marktredwitz, DE /ID# 240455</name>
      <address>
        <city>Marktredwitz</city>
        <zip>95615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHIO Forschungsinstitut /ID# 240525</name>
      <address>
        <city>Meerbusch</city>
        <zip>40668</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof-med-stud.de /ID# 240458</name>
      <address>
        <city>Munich</city>
        <zip>80935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Facharztpraxis /ID# 240477</name>
      <address>
        <city>Naumburg (Saale)</city>
        <zip>06618</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med Thilo Klopsch /ID# 240461</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wagener &amp; Hein, Nienburg, DE /ID# 240456</name>
      <address>
        <city>Nienburg</city>
        <zip>31582</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ für Rheumatologie Dr. M. Welcker GmbH /ID# 240521</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Dr. Prothmann /ID# 240671</name>
      <address>
        <city>Püttlingen</city>
        <zip>66346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ratingen /ID# 240465</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Gemeinschaftspraxis Schwerin /ID# 240463</name>
      <address>
        <city>Schwerin</city>
        <zip>19053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melzer, Seesen, DE /ID# 240484</name>
      <address>
        <city>Seesen</city>
        <zip>38723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Magdea /ID# 240482</name>
      <address>
        <city>Stadtoldendorf</city>
        <zip>37627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barmherzige Bruder MVZ Klinikum Straubing GmbH /ID# 240523</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpraxis /ID# 240564</name>
      <address>
        <city>Stuttgart</city>
        <zip>70372</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruederkrankenhaus Trier /ID# 240524</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumathologie Ulm /ID# 240494</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Josef /ID# 240522</name>
      <address>
        <city>Wuppertal</city>
        <zip>42105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Barmen /ID# 240449</name>
      <address>
        <city>Wuppertal</city>
        <zip>42285</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sprekeler, Zeven, DE /ID# 240519</name>
      <address>
        <city>Zeven</city>
        <zip>27404</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fricke-Wagner, Zwickau, DE /ID# 240452</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiographic Axial Spondylarthritis (r-axSpA)</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>RINVOQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

